Aaron B. Cowley

Chief Scientific Officer, ReciBioPharm

Aaron B. Cowley is an accomplished professional with a diverse background in chemistry, biotechnology, and business. As the Chief Scientific Officer at ReciBioPharm, he plays a crucial role in leading the company’s efforts in Advanced Therapy Medicinal Products (ATMP), including Live Biotherapeutic Products, xRNA, Viral Vectors, Enzymes, and pDNA. With his expertise in redox potentiometry and enzyme function, Aaron has made significant contributions to the field, resulting in publications, patents, grant funds, and venture capital funding.

Prior to his current role, Aaron co-founded Captozyme, a successful biotechnology company that was later acquired by Arranta Bio. He also played a key role at Oxidien Pharmaceuticals, another biotech company that was acquired in 2023. His involvement in the development of continuous manufacturing platforms for xRNA at ReciBioPharm, as well as his contributions to the MIT Center of Continuous mRNA Manufacturing, demonstrate his commitment to innovative scientific and business strategies.